USHER SYNDROME COALITION



- Jul 23, 2022
Potential of endogenous regenerative technology for in situ regenerative medicine

- Jun 17, 2022
A new hope for a therapy against retinitis pigmentosa

- Apr 30, 2022
Retinal Phenotype of Patients with CLRN1-Associated Usher 3A Syndrome in French Light4Deaf Cohort


- Mar 18, 2022
Antabuse may help revive vision in people with progressive blinding disorders

- Jan 31, 2022
MalaCards: The human disease database

- Jan 31, 2022
ProQR seeking Clinical Trial Participants

- Jan 24, 2022
RPGR and X-linked Retinitis Pigmentosa

- Jan 19, 2022
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

- Jan 1, 2022
Retinitis Pigmentosa Pathway

- Dec 21, 2021
First patients dosed in phase 2/3 gene therapy trial for retinitis pigmentosa

- Sep 16, 2021
Coave Therapeutics and Théa Open Innovation sign exclusive agreement

- Aug 16, 2021
New Treatments for Retinitis Pigmentosa

- Jul 28, 2021
Pre-mRNA Processing Factors and Retinitis Pigmentosa: RNA Splicing and Beyond


- Jul 13, 2021
CRISPR/Cas9 Gene Editing

- Jul 5, 2021
The Lrat−/− Rat: CRISPR/Cas9 Construction and Phenotyping of a New Animal Model for RP

- Jun 28, 2021
Broadening INPP5E phenotypic spectrum:

- May 24, 2021
Clinical Trial News: Positive results in Usher syndrome and RP clinical study


- May 10, 2021
2021 Spring Fundraiser - April 24th


- Apr 26, 2021
An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis